KAICO Partners with Baiya Phytopharm through MoU on Protein Expression Services
Fukuoka, Japan, October 8, 2025 – KAICO Ltd. (“KAICO”) is pleased to announce it has signed a Memorandum of Understanding (MoU) with Baiya Phytopharm (“Baiya”) to collaboratively explore and develop complementary strategies in the field of recombinant protein expression services. Under this MoU, both companies will work together to expand service offerings, deepen technical cooperation, and accelerate the translation of novel biologics.
Under the MoU, KAICO and Baiya have agreed to focus on:
1. Referral of Projects on the Contract Protein Expression Service
2. Mutual Complementation of Reagent Lineups
Through this MoU, KAICO and Baiya aim to:
- Leverage complementary strengths—KAICO’s silkworm-baculovirus expression system and Baiya’s plant-based system—to offer broader choices and enhanced capacity.
- Expand each party’s geographic reach and customer base via reagent cross-licensing and project referrals.
About Baiya Phytopharm
Baiya Phytopharm, established in 2018 as a spin-off from Chulalongkorn University in Thailand, is a clinical-stage biopharmaceutical company that leverages its proprietary BaiyaPharming™ plant-based platform to develop therapeutics, vaccines, and recombinant proteins.
Baiya’s platform has demonstrated speed and flexibility in producing biologic molecules and has advanced multiple pipeline candidates including multifunctional antibody derivatives in immuno-oncology and infectious disease fields. Their Bangkok facility is among the few plant-based cGMP-certified manufacturing sites in Asia.
About KAICO
KAICO, founded as a startup from Kyushu University, advances a proprietary silkworm–baculovirus expression system, using silkworm pupae as bioreactors for recombinant protein production. The company offers custom protein expression services, research reagents, and is actively developing vaccine candidates for both veterinary and human health applications.
Leveraging this agreement as a catalyst, KAICO remains committed to expanding strategic partnerships across alternative protein expression systems, human and animal healthcare and related fields, accelerating its journey toward impactful innovation.